The new Right to Try Act was signed into law on May 30, 2018. This act builds on the foundation of the governments Expanded Access programs, that we previously wrote about here. Previously, if a patient with a terminal illness was seeking an experimental treatment under the Expanded Access program, their doctor was required to initiate a request for the treatment. The request needed several different approvals, first from the pharmaceutical company manufacturing the drug, then from the FDA, and finally from the investigational review board (IRB) of the institution where they would be receiving it. This process was tedious and time consuming, especially for terminally ill patients, and very busy physicians.
The Right to Try Act removes the need for IRB and FDA Approval, making the process much more straightforward for physicians and their patients requesting experimental treatments. There are still some limitations with Right to Try - pharmaceutical companies cannot be required to provide their treatments to patients, and some pharmaceutical companies, even if they approve the request, may pass along the cost of manufacturing and shipping the drug to the patient - although Right to Try prevents them from profiting of the request. Additionally, the cost of receiving the therapy may not be covered by private insurances, Medicare or Medicaid. In order to be eligible for consideration under the Right to Try Act, patients and investigational drugs must meet certain criteria.
An eligible patient is a patient who has:
An eligible investigational drug is an investigational drug:
With this law being passed so recently, details about how to use the Right to Try Act are sometimes hard to find. You can always call us at SparkCures (888) 828-2206, and we will be happy to help you find the answers you need.
If you are interested in learning more about the recently passed Right to Try Act, you can view the FDAs Right to Try Act page here. You can find the law in its entirety here.
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.